CEO Terry Novak calls for science-backed standards to meet patient needs

Austin, TX — September 29, 2025 — This week, a widely shared video featuring President Trump highlighted the potential medical benefits of cannabis for seniors. For millions of older adults, cannabinoids are already part of their daily search for relief from pain, arthritis, anxiety, and sleep disorders. The growing visibility of this conversation underscores how quickly public awareness is catching up to patient reality.

“The senior health conversation is just the beginning,” said Terry Novak, CEO of Benuvia. “With the right standards and partnerships, cannabinoids can move from headlines to healthcare and transform patient care across neurology, pain management, oncology, and beyond.”

Benuvia believes this moment marks a critical shift in how society approaches cannabinoid medicine. While many patients already recognize the benefits, what’s missing are the pharmaceutical standards and regulatory frameworks that transform promising compounds into reliable therapies.

“The fact that this discussion has reached such a broad audience shows how urgently patients are looking for answers,” Novak added. “But awareness is not enough. Seniors deserve medicines they can trust,medicines that are consistent, safe, and backed by science. Rescheduling cannabis would enable the FDA to regulate these therapies and finally bring clarity, confidence, and quality to the patients who need them most.”

Benuvia’s Capabilities in Cannabinoid Medicine

As a U.S.-based CDMO with deep expertise in controlled substances and small molecules, Benuvia is prepared to support this shift with:

GMP Manufacturing — APIs and finished dosage forms produced to pharmaceutical standards of purity and consistency.
Clinical Development Support — IND-ready materials, advanced formulation capabilities, and stability testing to accelerate innovation.
Regulatory Strength — Proven expertise navigating DEA and FDA requirements to ensure safety, compliance, and reliability.
Partnership Across the Lifecycle — From early development through commercial supply, Benuvia partners with innovators to turn promising science into trusted therapies.

About Benuvia Operations, LLC

Benuvia is a U.S.-based contract development and manufacturing organization (CDMO) headquartered in Austin, Texas. Specializing in controlled substances and small molecules, Benuvia supports pharmaceutical innovators from early-stage development through commercial manufacturing. The company’s capabilities span API production, finished dosage form development, stability testing, and regulatory strategy, ensuring quality, compliance, and speed to market.
Learn more at www.benuvia.com.